Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Brickell Biotech, Inc. (Nasdaq: BBI) has announced it has regained compliance with Nasdaq's minimum bid price requirement, thereby avoiding potential delisting. The scheduled hearing regarding its compliance has been canceled, allowing Brickell’s common stock to continue trading on Nasdaq. The company is focused on developing innovative therapeutics for autoimmune and inflammatory diseases, with a robust pipeline and experienced management team.

Positive

• Regained compliance with Nasdaq's minimum bid price requirement.
• Scheduled hearing on compliance canceled, ensuring continued trading on Nasdaq.
• Focused on innovative therapeutics for autoimmune and inflammatory diseases.

Negative

• None.

BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement for continued listing on Nasdaq and, accordingly, the scheduled hearing has been canceled and Brickell’s common stock will continue to be listed and traded on Nasdaq.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Brickell’s pipeline consists of several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^®, Juvederm^® and Pluvicto^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that Brickell believes can meaningfully benefit patients who are suffering from chronic, debilitating diseases that are underserved by available therapies. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

FAQ

What recent compliance news did Brickell Biotech (BBI) announce?

Brickell Biotech announced that it has regained compliance with Nasdaq's minimum bid price requirement.

What was the outcome of Brickell Biotech's scheduled hearing with Nasdaq?

The scheduled hearing has been canceled due to Brickell's compliance with Nasdaq requirements.

Why is compliance with Nasdaq important for Brickell Biotech (BBI)?

Compliance with Nasdaq requirements ensures that Brickell Biotech's common stock can continue to be listed and traded on the exchange.

What does Brickell Biotech focus on in its business operations?

Brickell Biotech focuses on developing innovative therapeutics for autoimmune and inflammatory diseases.